An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Completed · Phase 3

Conditions studied: Cushing's Syndrome

In brief

Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator.

Key facts

Study ID

NCT00936741

Run by

Corcept Therapeutics

People needed

30

Starts

2009-07-01

Expected to finish

2012-09-01

Last updated by the study team

2014-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed the Week 24 visit and the 6-Week Follow-up visit of Corcept Study C-1073-400 (NCT00569582).
• In the opinion of the Investigator, are expected to maintain clinical benefit from mifepristone.
• Women of childbearing potential have a negative serum pregnancy test at Entry.
• Women of childbearing potential must be willing to use non-hormonal, medically acceptable methods of contraception during the study.
• Are able to provide written informed consent
• Are able to return to the investigative site to complete the study evaluations outlined in the protocol.
• Will not use systemic estrogens during the study.

You may not qualify if…

• Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.
• Are taking medications within 14 days of the Entry visit that a) have a large first pass metabolism that is largely mediated by CYP3A4 and which have a narrow therapeutic margin; and/or b) are strong CYP3A4 inhibitors.
• Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.
• Have received investigational treatment (drug, biological agent or device) other than CORLUX (mifepristone) within 30 days of Entry
• Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)
• Have uncorrected hypokalemia (potassium level of <3.5 mEq/L) at Entry. Spironolactone or eplerenone is allowed to control hypokalemia.
• Postmenopausal women with a history of endometrial hyperplasia with atypia or pathological features consistent with endometrial carcinoma.
• Thickened endometrium on the Entry Visit transvaginal ultrasound that has not resolved after induction of menstrual bleeding with progesterone.
• Uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
• Any woman with an intact uterus who has a hemorrhagic disorder or is being treated with an anticoagulant (e.g. warfarin, heparin).
• Have renal failure as defined by a serum creatinine of ≥2.2 mg/dL.
• Elevated total bilirubin >1.5 ULN, elevated ALT or AST ≥3X the upper limit of normal.

Where it is running

• University of Alabama at Birmingham School of Medicine — Birmingham, Alabama, United States
• AMCR Institute Inc. — Escondido, California, United States
• Stanford University Medical Center — Stanford, California, United States
• The Center for Diabetes and Endocrine Care — Hollywood, Florida, United States
• Northwestern University Feinberg Medical; Division of Endocrinology, Metabolism & Molecular Medicine — Chicago, Illinois, United States
• Sinai Hospital of Baltimore — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• University of New Mexico — Albuquerque, New Mexico, United States
• Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism — Cleveland, Ohio, United States
• Oklahoma Diabetes Center — Oklahoma City, Oklahoma, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• University of Texas Southwestern Medical Center — Dallas, Texas, United States
• Endocrinology Center at Community Medical Commons — Menomonee Falls, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.